Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined 162 patients and found that those with both alopecia areata and atopic diseases showed higher cases of severe alopecia in children and a tendency for combined atopic diseases. Sensitization patterns were similar between alopecia areata patients and those with atopic diseases alone.

This study found a consistent association between atopic dermatitis and obesity, while links with other metabolic syndrome components like dyslipidemia and hypertension were inconsistent, indicating the need for targeted metabolic screening, particularly in moderate-to-severe cases.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This study found that topical immunotherapy was effective in 56.83% of pediatric patients with alopecia areata, but those with co-occurring atopic dermatitis were more likely to show an inadequate response to treatment.

This commentary piece identifies interleukin-13 as a potential therapeutic target for treating alopecia areata associated with atopic dermatitis, although specific study results or outcomes are not provided in the abstract.

In this study, topical application of adipose stem cell exosomes was found to reduce facial redness in atopic dermatitis patients treated with dupilumab, while improving skin hydration and decreasing inflammation markers over 12 weeks.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

Adipose stem cell exosomes may effectively treat atopic dermatitis by reducing inflammation and improving skin health.

This study observed mixed responses to dupilumab in patients with both atopic dermatitis and alopecia areata, suggesting a potential role for Th2 axis dysregulation in alopecia areata.

In this laboratory study, researchers developed and tested two in vitro models to simulate atopic dermatitis using HaCaT cells, finding that azithromycin displayed epithelial-strengthening properties in one model, potentially offering insights for future research on skin disease interventions.

This study reports that improvements to the EczemaNet pipeline, incorporating pixel-level segmentation and data augmentation, enhanced the reliability and interpretability of assessing atopic dermatitis severity from digital images.

This study found that adults with atopic dermatitis who were treated with baricitinib at doses of 2mg or 4mg experienced significant improvements in work productivity, potentially leading to substantial indirect cost savings for employers over 16 weeks.

This study found that innate lymphoid cells-type 1 can induce alopecia areata characteristics in human hair follicles both ex vivo and in vivo, challenging the view of it as solely an autoimmune disease driven by CD8+ T cells.

This case study reports significant improvement in severe atopic dermatitis and alopecia areata symptoms in a patient treated with dupilumab, highlighting the potential for patient selection in optimizing therapeutic outcomes.

This review outlines the potential of mesenchymal stem cells and their derivatives as emerging therapies for atopic dermatitis, but reports no new clinical results; the authors highlight the need for further investigation.

This study found that CD1a-restricted CD4+ T cells responsive to lysyl-phosphatidylglycerol were more frequent in the blood of atopic dermatitis patients, suggesting a potential role in the disease's Th2-mediated pathology.

This study found that spatial transcriptomics can reveal hidden inflammation patterns in atopic dermatitis by correlating epidermal and dermal gene expression levels, improving understanding of skin pathology.

This study established a mouse model of atopic dermatitis with overgrowth of Malassezia globosa using olive oil as a vehicle, which caused severe lesions and hair follicle damage.

This study found that neutrophils are crucial for initiating chronic itch in atopic dermatitis and suggest that targeting neutrophils may help alleviate symptoms in this condition.

This case report describes a 6-year-old child with twenty nail dystrophy and alopecia areata of the scalp.

This study suggests that dietary grape powder may reduce the severity of atopic dermatitis in a mouse model, highlighting its potential in both prevention and intervention settings.

In this study, researchers observed a strong association between keloid scars and atopic dermatitis, suggesting a link between keloids and signs of atopy in a diverse patient population.

The electronic version of the Dermatology Life Quality Index is as effective as the paper version, with most patients preferring it.

The new cream is safe and effective for mild to moderate atopic dermatitis.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

In this study, the novel isoprenylcysteine analog SIG-1451 was shown to inhibit pro-inflammatory cytokine release in various cell-based assays relevant to allergic dermatitis, acting on targets such as IL-4 and IL-6 with potential anti-inflammatory benefits.

This report highlights a case of disseminated and recurrent infundibulofolliculitis in a 45-year-old African American male and underscores the importance of performing a skin biopsy for diagnosis.

This study found that an anti-atopic lotion containing fucoidan helped heal skin damage in hairless mice with atopic dermatitis by reducing skin thickness and modulating immune responses.

Atopic dermatitis significantly lowers the quality of life for infants and their families.